Efficacy and safety of avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective cohort study in Japan

Efficacy and safety of avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective cohort study in Japan

Abstract Background Avacopan, an oral C5a receptor antagonist, demonstrated efficacy as an alternative to glucocorticoid therapy in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in the phase 3 ADVOCATE trial. However, limited real-world data exist on the outcom...

Full description

Saved in:
Bibliographic Details
Main Authors: Genri Tagami, Makoto Yamaguchi, Hirokazu Sugiyama, Hiroshi Kinashi, Kentaro Imai, Keisuke Kamiya, Takayuki Katsuno, Takahiro Imaizumi, Shogo Banno, Yasuhiko Ito, Takuji Ishimoto
Format: Article
Language:English
Published: BMC 2025-01-01
Series:BMC Rheumatology
Subjects:
Antineutrophil cytoplasmic autoantibody-associated vasculitis
Avacopan
Efficacy
Remission
Safety
Online Access:https://doi.org/10.1186/s41927-025-00456-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s41927-025-00456-4

Similar Items